Publicaciones en las que colabora con Jose Gonzalez Campos (15)

2024

  1. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

  2. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

    HemaSphere

2022

  1. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Blood Advances, Vol. 6, Núm. 18, pp. 5395-5402

  2. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675

2020

  1. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169

2019

  1. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

    Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035

  2. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

    Genes Chromosomes and Cancer, Vol. 58, Núm. 11, pp. 815-819

  3. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry

    Leukemia and Lymphoma, Vol. 60, Núm. 11, pp. 2720-2732

  4. The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

    British Journal of Haematology, Vol. 186, Núm. 2, pp. 263-268

2018

  1. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

  2. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

    Leukemia, Vol. 32, Núm. 1, pp. 21-29

2017

  1. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

    Annals of hematology, Vol. 96, Núm. 7, pp. 1069-1075

2015

  1. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

    Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356

  2. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

    Cancer, Vol. 121, Núm. 21, pp. 3809-3817

2011

  1. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477